Published in J Infect Dis on March 01, 1981
Cefoxitin inactivation by Bacteroides fragilis. Antimicrob Agents Chemother (1983) 2.64
Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis (2008) 1.40
Interactions with fibronectin attenuate the virulence of Streptococcus pyogenes. EMBO J (2004) 1.12
Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother (1989) 0.88
Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron. Antimicrob Agents Chemother (2004) 0.82
In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. Sci Rep (2015) 0.81
Rifampin blood and tissue levels in patients undergoing cardiac valve surgery. Antimicrob Agents Chemother (1982) 0.78
Cephalosporins in surgery. Prophylaxis and therapy. Drugs (1987) 0.76
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother (1975) 8.86
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Anaerobic infections. 1. N Engl J Med (1974) 8.02
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Glanders in a military research microbiologist. N Engl J Med (2001) 4.77
Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med (1995) 4.42
Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis (1979) 4.39
Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology (1981) 4.04
Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93
Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun (1974) 3.91
Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89
Quantitative bacteriology of the vaginal flora. J Infect Dis (1977) 3.81
Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med (2001) 3.75
Management of anaerobic infections. Ann Intern Med (1975) 3.62
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34
Anaerobic pleuropulmonary infections. Medicine (Baltimore) (1972) 3.30
Microbial synergy in experimental intra-abdominal abscess. Infect Immun (1976) 3.21
Anaerobic infections (second of three parts). N Engl J Med (1974) 3.18
Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med (2001) 3.15
Colitis induced by Clostridium difficile. Rev Infect Dis (1980) 3.15
Anaerobic infections (third of three parts). N Engl J Med (1974) 3.13
Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis (1984) 3.07
Treatment of anaerobic infections with lincomycin and clindamycin. N Engl J Med (1972) 3.05
Antibiotic-associated pseudomembranous colitis. Rev Infect Dis (1980) 3.02
Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet (1978) 2.87
Gram negative species associated with active destructive periodontal lesions. J Clin Periodontol (1985) 2.86
Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J Clin Microbiol (1979) 2.86
Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med (1977) 2.73
The parasitophorous vacuole membrane surrounding intracellular Toxoplasma gondii functions as a molecular sieve. Proc Natl Acad Sci U S A (1994) 2.70
Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology (1980) 2.60
Antimicrobial therapy of experimental intraabdominal sepsis. J Infect Dis (1975) 2.56
Anaerobic infections of the lung and pleural space. Am Rev Respir Dis (1974) 2.46
Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance. J Clin Invest (1988) 2.38
Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA (1998) 2.37
Preoperative oral antibiotics reduce septic complications of colon operations: results of prospective, randomized, double-blind clinical study. Ann Surg (1977) 2.36
Experimental intra-abdominal abscesses in rats: quantitative bacteriology of infected animals. Infect Immun (1974) 2.33
Partial purification and characterization of a cytotoxin from Clostridium difficile. Rev Infect Dis (1980) 2.31
The Toxoplasma gondii rhoptry protein ROP 2 is inserted into the parasitophorous vacuole membrane, surrounding the intracellular parasite, and is exposed to the host cell cytoplasm. J Cell Biol (1994) 2.26
Rapid microbiological assay for chloramphenicol and tetracyclines. Antimicrob Agents Chemother (1976) 2.26
The type I macrophage scavenger receptor binds to gram-positive bacteria and recognizes lipoteichoic acid. Proc Natl Acad Sci U S A (1994) 2.22
Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol (1989) 2.18
Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med (2001) 2.17
Clostridium difficile in gnotobiotic mice. Infect Immun (1980) 2.17
Association of host cell endoplasmic reticulum and mitochondria with the Toxoplasma gondii parasitophorous vacuole membrane: a high affinity interaction. J Cell Sci (1997) 2.16
AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea. Ann Intern Med (1991) 2.13
Safe haven: the cell biology of nonfusogenic pathogen vacuoles. Annu Rev Microbiol (1997) 2.07
Methods for quantitative vaginal flora studies. Am J Obstet Gynecol (1977) 2.05
Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis (1983) 2.03
Bacteriology of empyema. Lancet (1974) 2.00
Probenecid and zidovudine metabolism. Lancet (1989) 1.99
Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology (1978) 1.98
Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. J Cell Biol (2000) 1.96
Lipopolysaccharide size and distribution determine serum resistance in Salmonella montevideo. J Bacteriol (1987) 1.93
Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. Gastroenterology (1988) 1.93
In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother (1980) 1.89
Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults: background. Ann Intern Med (2001) 1.89
Is Clostridium difficile endemic in chronic-care facilities? Lancet (1986) 1.88
Anaerobes survive in clinical specimens despite delayed processing. J Clin Microbiol (1976) 1.87
Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol (1984) 1.87
C3 binds preferentially to long-chain lipopolysaccharide during alternative pathway activation by Salmonella montevideo. J Immunol (1986) 1.82
Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1987) 1.82
Update on Department of Health and Human Services guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Hopkins HIV Rep (1999) 1.81
The role of the intestinal microflora in experimental colitis. Am J Clin Nutr (1977) 1.80
Detection of Clostridium botulinum type A toxin by enzyme-linked immunosorbent assay with antibodies produced in immunologically tolerant animals. J Clin Microbiol (1984) 1.77
Kinetics and pattern of organelle exocytosis during Toxoplasma gondii/host-cell interaction. Parasitol Res (1993) 1.76
Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology (1989) 1.76
A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am Rev Respir Dis (1979) 1.76
Bacteriological studies of experimental ulcerative colitis. Am J Clin Nutr (1979) 1.75
Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann Intern Med (1976) 1.73
The parasitophorous vacuole membrane surrounding Plasmodium and Toxoplasma: an unusual compartment in infected cells. J Cell Sci (1998) 1.73
CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J Immunol (1989) 1.72
Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea of colitis. Johns Hopkins Med J (1981) 1.69
The Toxoplasma gondii protein ROP2 mediates host organelle association with the parasitophorous vacuole membrane. J Cell Biol (2001) 1.69
Practice guidelines for evaluating new fever in critically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America. Clin Infect Dis (1998) 1.67
Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing Clostridia. Am J Vet Res (1978) 1.66
Targeting to rhoptry organelles of Toxoplasma gondii involves evolutionarily conserved mechanisms. Nat Cell Biol (2000) 1.57
Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team. Chest (1998) 1.57
Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med (2001) 1.55
Comparison of five regimens for treatment of experimental clindamycin-associated colitis. J Infect Dis (1978) 1.54
The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. Chest (1995) 1.53
Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect Immun (1983) 1.51
Complement binding by two developmental stages of Leishmania major promastigotes varying in expression of a surface lipophosphoglycan. J Exp Med (1988) 1.51
Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50
The triple threat of aspiration pneumonia. Chest (1975) 1.48
Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella. J Clin Invest (1989) 1.47
Bacteriology and treatment of primary lung abscess. Am Rev Respir Dis (1974) 1.46
Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J Clin Invest (1995) 1.45
Bacteriology of hospital-acquired pneumonia. Arch Intern Med (1986) 1.45